Publications

5891 Results

Utilization of genomic tumor testing (GTT) among community oncologists participating in SWOG S2108CD

Authors
M Trivedi;A Michel;J Unger;S Colby;L Graham;K Reed;J Fischer;B Symington;S Ramsey;D Hershman;J Rueter
Journal / Conference
ASCO Quality of Care Symposium (September 27-28, 2024, San Francisco, CA), poster;JCO Oncol Pract 20, 2024 (suppl 10; abstr 320)
Year
2024
Research Committee(s)
Cancer Care Delivery
Study Number(s)
S2108CD

The Cost of Doing Business – Drug Costs in Federally-Sponsored Cancer Clinical Trials

Authors
J Unger;H Xiao;R Vaidya;S Threlkel;M Chansky;A Hayes;D Hershman;M LeBlanc
Journal / Conference
ASCO Quality of Care Symposium (September 27-28, 2024, San Francisco, CA), poster; JCO Oncol Pract 20, 2024 (suppl 10; abstr 10)
Year
2024
Research Committee(s)
Cancer Care Delivery

Correlations Between Baseline Tumor Burden and Overall Survival in Patients with Rare Cancers Treated with Immune Checkpoint Inhibitors (NCI/SWOG S1609)

Authors
P Swiecicki;M Othus;S Patel;Y Chae;R Kurzrock
Journal / Conference
SITC (Nov. 6-10, Houston, TX), poster
Year
2024
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S1609

Progression-Free Survival (PFS) with Nivolumab-AVD is superior to Brentuximab Vedotin-AVD with 2-year follow-up of S1826 in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL)

Authors
S Castellino;H Li;A Herrera;A Punnett;M LeBlanc;S Parsons;F Keller;R Drachtman;A Lambert;C Forlenza;A Doan;S Rutherford;A Evens;D Hodgson;R Little;M Smith;H Dillon;J Song;S Smith;J Friedberg;K Kelly
Journal / Conference
ISHL (October 26-28, Cologne, Germany), oral
Year
2024
Research Committee(s)
Lymphoma
Study Number(s)
S1826

Nivolumab-AVD improves 2-year progression-free and overall survival compared to Bv-AVD in older patients (aged =60 years) with advanced stage Hodgkin lymphoma enrolled on SWOG S1826

Authors
S Rutherford;H Li;A Herrera;M LeBlanc;S Ahmed;K Davison;C Casulo;N Bartlett;J Tuscano;B Hess;P Torka;P Kumar;R Jacobs;J Song;B Kahl;J Leonard;S Smith;JW Friedberg;A Evens
Journal / Conference
ISHL (October 26-28, Cologne, Germany), oral
Year
2024
Research Committee(s)
Lymphoma
Study Number(s)
S1826

Factors Influencing Additional Nodal Disease and Pathologic Nodal Upstaging with Axillary Dissection in Patients with Residual Node Positive Breast Cancer After Neoadjuvant Chemotherapy Enrolled on Alliance A011202 Clinical Trial

Authors
J Boughey;V Suman;K Hunt;B Haffty;T Buchholz;F Symmons;T Rieken;T Dockter;J Campbell;J Bradley;J Mammen;A Partridge;L Carey
Journal / Conference
San Antonio Breast Cancer Symposium (December 10-13, 2024, San Antonio, TX), poster
Year
2024
Research Committee(s)
Breast
Study Number(s)
CTSU/A011202

Effect of a weight loss intervention (WLI) on metabolic and inflammatory biomarkers in women with obesity and breast cancer: Results from the Breast Cancer Weight Loss (BWEL) Trial

Authors
J Ligibel;K Ballman;L McCall;L Lu;P Goodwin;C Alfano;V Bernstein;T Crane;L Delahanty;E Frank;O Hahn;D Hershman;J Hopkins;E Mayer;L Minasian;L Nebeling;M Neuhouser;E Paskett;P Spears;V Stearns;C Thomson;A Weiss;J White;T Wadden;C Hudis;E Winer;L Carey;A Partridge
Journal / Conference
San Antonio Breast Cancer Symposium (December 10-13, 2024, San Antonio, TX), poster
Year
2024
Research Committee(s)
Breast
Study Number(s)
CTSU/A011401

Ability to comply with placebo predicts overall survival

Authors
T Sanft;J Miao;A Meisner;W Barlow;M Chavez MacGregor
Journal / Conference
San Antonio Breast Cancer Symposium (December 10-13, 2024, San Antonio, TX), poster
Year
2024
Research Committee(s)
Breast
Study Number(s)
S1207

Long-Term Follow-up and updated analysis from S0221, Comparing Alternative Dose-Schedules of Adjuvant Anthracyclne/Taxane Therapy in High-Risk Early Breast Cancer

Authors
A Ali;W Barlow;HCF Moore;T Hobday;J Stewart;C Isaacs;M Salim;J Cho;K Rinn;K Albain;H Chew;G Burton;T Moore;G Srkalovic;B McGregor;L Flaherty;DL Lew;J Gralow;G Hortobagyi;P Sharma;L Pusztai;G Budd
Journal / Conference
San Antonio Breast Cancer Symposium (December 10-13, 2024, San Antonio, TX), rapid fire presentation (oral)
Year
2024
Research Committee(s)
Breast
Study Number(s)
S0221

Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Younger Patients with Mantle Cell Lymphoma: Clinical Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181

Authors
N Wagner-Johnston;O Jegede;S Spurgeon;K Maddocks;D Yang;J Romanoff;J Paludo;P Caimi;N Bartlett;P Reagan;Y Sawalha;M Hoffmann;B Hu;A Aziz;H Marques;L Kostakoglu Shields;J Leonard;JW Friedberg;B Kahl
Journal / Conference
ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), oral
Year
2024
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/EA8141